West Pharmaceutical Services has opened a 165,000 square foot expansion at its Damastown site in Dublin, adding advanced automation and commercial-scale drug handling capacity aimed at high-volume injectable treatments for diabetes and obesity.
The new space gives West more room to serve a market that has been growing fast, but the share price has not kept pace with the story. The stock was trading at US$254.80 after a 7.81% decline over 90 days, even though its one-year total shareholder return stood at 16.24%.
The expansion matters because it lands at the center of West’s long-running push into higher-value drug delivery and contract manufacturing. The company’s most followed narrative points to a fair value of $338.57 a share, above the average analyst target of US$316.69, while the market still values the stock at 37.2 times earnings. That sits above the 33.8x average for the North American Life Sciences industry and the 30x peer average, though it is still well above the fair ratio of 20x.
That gap is where the debate now lives. West carries a low value score of 1, and investors are being asked to judge whether the Dublin expansion can do what the company says it should: help drive revenue and net margins through rising demand, a shift toward higher-margin HVP components and about 340 Annex 1 projects. The same narrative also says the move deeper into contract manufacturing and drug handling could improve margins and earnings after the initial ramp-up period.
For now, the message from Dublin is clear: West is spending for growth in a specialized corner of the drug supply chain, even as the valuation leaves little room for disappointment. The next test is whether the new capacity turns into the kind of margin lift investors are already paying for.
